The European Commission tabled its review of the pending, $13.35 billion merger between Zimmer (NYSE:ZMH) and Biomet, saying Zimmer’s submission for the June 3 review was insufficient.
Biomet
Zimmer looks to avoid layoffs in Biomet merger | Medtech personnel moves for the week of May 26, 2014
Op-Ed: How to survive the Zimmer/Biomet merger
Layoffs: Zimmer aims to ‘keep everybody’ following $13.3B Biomet mega-merger
Biomet CEO: Medtech helps curb healthcare costs | MassDevice.com On Call
MASSDEVICE ON CALL — Recent data exposures from the Centers for Medicare & Medicaid have raised eyebrows about the cost of U.S. healthcare and variability among care providers, but Biomet CEO Jeffrey Binder insists that medical devices are not to blame.
In a new editorial written for Philly.com, Binder defended the industry and its role in the ever-rising cost of U.S. healthcare, writing that medtech more often helps curb costs by keeping people healthier longer and out of the hospital.
Medtech trends: The most talked about device makers in April 2014
C.R. Bard posted major profit growth in its 1st quarter | Medtech Wall Street news for the week of Apr. 28, 2014
The new face of ortho: Zimmer to take 2nd place with $13.4B Biomet buy
Zimmer beats The Street, alters 2014 forecast on Biomet buy
Ortho shakeup: Zimmer to acquire Biomet in deal worth $13.35 billion
Biomet slashes Q3 losses, sales rise nearly 7%
Biomet said today that it slashed its 3rd-quarter losses by nearly 80% and boosted sales by 6.6% as the privately-owned orthopedics giant prepares to go back on the stock market.
Warsaw, Ind.-based Biomet posted losses of -$65.9 million on sales of $822.5 million for the 3 months ended Feb. 28. Adjusted to exclude 1-time items, profits rose 13.1% compared with the same period last year, to $107.3 million.